Guardant Health, Inc. (GH) Expands Liquid Biopsy to Pinpoint Tumor Origins and Biomarkers

Guardant Health, Inc. (NASDAQ:GH) has introduced major upgrades to its Guardant360 Liquid biopsy test, significantly expanding its cancer biomarker detection and subtyping abilities. Utilizing the Guardant Infinity platform and AI-driven analysis, the test now offers comprehensive multiomic profiling from a simple blood draw.

Guardant Health, Inc. (NASDAQ:GH) Expands Liquid Biopsy to Pinpoint Tumor Origins and Biomarkers

A patient viewing their medical diagnosis on a digital healthcare ecosystem.

The enhanced test helps doctors quickly exclude actionable mutations in lung and colorectal cancers, identify cancer origins when unknown, and accurately classify breast and lung cancer subtypes through tumor methylation patterns. It also integrates pharmacogenomic data to guide safe drug use, detects viruses like HPV and EBV affecting treatment, assesses Homologous Recombination Deficiency (HRD) for targeted therapies, and uses HLA genotyping to inform therapy choices and clinical trial options.

Guardant Health, Inc. (NASDAQ:GH)’s co-CEO Helmy Eltoukhy highlighted that this blood-based test provides vital tumor insights without needing tissue samples, delivering results within seven days and enabling faster, smarter cancer treatment decisions.

While we acknowledge the potential of GH to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk.  If you are looking for an AI stock that is more promising than GH and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Cancer Stocks to Invest in for Long-Term Gains and 10 Most Oversold Stocks to Buy According to Billionaires.

Disclosure: None.